in almost 50% of cases. INI-1 is deficient in approximately 90% of cases.\textsuperscript{1,4} Complete surgical resection is the basis of curative therapy for ES. Some authors strongly recommend radical local excision, with amputation, as the first operative procedure.\textsuperscript{5} The authors report a rare case of upper limb ES, with long evolution before the diagnosis; attention is drawn to the important role of the dermatologist in the clinical recognition of this neoplasm.

Financial support

None declared.

Authors’ contributions

Maraya de Jesus Semblano Bittencourt: Approval of the final version of the manuscript; collection, analysis, and interpretation of data; critical review of the literature; critical review of the manuscript.

Caren dos Santos Lima: Drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the literature; critical review of the manuscript.

Etanercept-induced palisaded neutrophilic granulomatous dermatitis\textsuperscript{☆,☆☆}

Dear Editor,

A 37-year-old female was referred to this hospital, complaining of fever and induration and swelling of the chest wall. She had rheumatoid arthritis and been treated with non-steroidal anti-inflammatory drugs and methotrexate for six years, as well as etanercept (25 mg per three weeks) for two years, prior to presentation. Physical examination revealed a reddish induration with tenderness and swelling of the left breast (Fig. 1). It was also accompanied by a number of tiny pustules. Laboratory data showed positive anti-nuclear antibody (1:160), elevated C-reactive protein (14.91 mg/dL), anti-SS-A antibodies (> 240 U/mL), and positive Schirmer’s test (left eye; 2 mm). The patient had not been diagnosed as having Sjögren’s syndrome until presentation at this hospital. A biopsy specimen showed basophilic degeneration of collagen fibers mixed with numerous nuclear debris in the upper dermis (Fig. 2). There was also mild interface dermatitis. Immunohistochemistry

Aline de Lima Days: Approval of the final version of the manuscript; Drafting and editing of the manuscript; intellectual participation in propaedeutic and/or therapeutic conduct of studied cases; critical review of the literature; critical review of the manuscript.

Camilla Côrrea Neri: Drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the literature; critical review of the manuscript.

Conflict of interest

None declared.

References


Maraya de Jesus Semblano Bittencourt , Caren dos Santos Lima , Aline de Lima Dias , Camilla Côrrea Neri

Department of Dermatology, Centro Universitário do Estado do Pará, Belém, PA, Brazil

\textsuperscript{☆} Corresponding author.
E-mail: dias.alinetima@gmail.com (A.L. Dias).

Received 21 January 2020; accepted 10 June 2020

Available online 19 November 2020

https://doi.org/10.1016/j.j.abd.2020.06.007

0365-0596/ © 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Although non-steroidal anti-inflammatory drugs and methotrexate, three months after stopping etanercept, she was free from recurrence.

In the present case, infiltrative erythema occurred in a patient with rheumatoid arthritis and Sjögren’s syndrome two years after starting treatment with etanercept, and the eruption has not occurred since the etanercept treatment was stopped. Histopathological examination revealed characteristic findings of palisaded neutrophilic granulomatous dermatitis (PNGD) and interface dermatitis. Considering the clinical course and the histopathological features, PNGD could be induced by etanercept in the present case. PNGD is a pathological concept characterized by an inflammation pattern showing a palisading infiltration of histiocyte surrounding areas of necrobiosis, which occasionally occurs in patients with autoimmune diseases such as rheumatoid arthritis, Sjögren’s syndrome, and eosinophilic granulomatosis with polyangiitis. To date, there have only been few reported cases of PNGD occurring after treatment with etanercept, including the present case. In contrast to other TNF-α inhibitors, etanercept, a receptor fusion protein, is considered not to strongly suppress TNF-α activity and this may enable TNF-α to form granuloma. Otherwise, etanercept may modulate cytokines other than TNF, which cannot be done by other TNF inhibitors. In addition, etanercept can enhance T-cell production of interferon-gamma, which is a key player in granuloma formation. By contrast, there are reports that adalimumab and infliximab also induce sarcoid or sarcoid-like granulomas, and thus other mechanisms leading to granuloma induction may exist. Further studies are necessary to clarify the mechanisms of TNF inhibitors-induced granulomatous diseases.

Financial support

None declared.

Authors’ contributions

Masato Ishikawa: Design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; critical review of the literature.
Toshiyuki Yamamoto: Approval of the final version of the manuscript; design and planning of the study.

Conflicts of interest

None declared.

References


Masato Ishikawa 🩹 *, Toshiyuki Yamamoto 🩹
Fukushima Medical University, Fukushima, Japan
*Corresponding author.
E-mail: ishimasa@fmu.ac.jp (M. Ishikawa).
Received 18 February 2020; accepted 16 June 2020
Available online 16 November 2020
https://doi.org/10.1016/j.abd.2020.06.005
0365-0596/ © 2020 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).